BioCentury | Dec 8, 2018

Path to opioid-free pain relief

To jump-start development of analgesics that can help stem the opioid crisis, companies want FDA’s upcoming guidelines to reduce uncertainty around outcomes that constitute clinically meaningful opioid sparing. But while an advisory panel put some...
BioCentury | Mar 24, 2014

Horizon's Irish jig

Horizon Pharma Inc. (NASDAQ:HZNP) thinks Vidara Therapeutics International Ltd. 's lone drug, Actimmune interferon gamma-1b, by itself justifies the $660 million price tag for last week's acquisition. Thus, Horizon expects it is getting the tax...
BC Week In Review | Feb 17, 2014
Company News

Cadence, Mallinckrodt deal

Specialty pharma Mallinckrodt will acquire Cadence for $14 per share in cash, or about $1.3 billion on a fully diluted basis. The price is a 26% premium to Cadence's close of $11.07 on Feb. 10,...
BioCentury | Feb 17, 2014

Highlights of weekly biotech stock moves

Regulatory milestones Cubist Pharmaceuticals Inc. (NASDAQ:CBST) was up $0.73 to $73.55 last week after FDA's Anti-Infective Drugs Advisory Committee said it will meet on March 31 to discuss a pair of NDAs covering IV and...
BC Extra | Feb 12, 2014
Top Story

Mallinckrodt to acquire Cadence

Specialty pharma Mallinckrodt plc (NYSE:MNK) gained $6.88 (12%) to $66.19 on Tuesday after announcing it will acquire Cadence Pharmaceuticals Inc. (NASDAQ:CADX) for $14 per share in cash, or about $1.3 billion on a fully diluted...
BC Week In Review | Nov 18, 2013
Company News

Cadence, Exela Pharma Sciences LLC neurology news

The U.S. District Court for the District of Delaware ruled in favor of Cadence in a patent infringement suit against Exela regarding Cadence's Ofirmev acetaminophen injection for pain and fever. In 2011, Cadence filed Cadence...
BioCentury | Nov 18, 2013

Highlights of weekly biotech stock moves

Regulatory milestones Algeta ASA (OSE:ALGETA) was off NOK4.60 to NOK263.40 on Friday after the European Commission approved an MAA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer...
BC Week In Review | Sep 2, 2013
Company News

Cadence neurology news

Cadence said the U.S. Patent and Trademark Office (PTO) made an initial determination to reject claims of U.S. Patent No. 6,028,222 in its ex parte reexamination of the patent. The '222 patent expires in August...
BC Week In Review | Mar 18, 2013
Clinical News

Ofirmev IV acetaminophen regulatory update

Cadence said that the U.S. Department of Veterans Affairs listed pain and fever drug Ofirmev acetaminophen on its VA National Formulary (VANF). The IV formulation of acetaminophen is approved in the U.S. to manage moderate...
BC Week In Review | Dec 17, 2012
Company News

Cadence, Incline Therapeutics, Medicines Co. deal

The Medicines Co. will acquire Incline for $185 million up front plus up to $205 million in milestones. The Medicines Co. will gain exclusive, worldwide rights to Ionsys fentanyl, which Incline licensed from the Alza...
Items per page:
1 - 10 of 114